This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We’re excited to share that metaMe Health , a prescription digitaltherapeutics (PDT) company, today announced raising $2.2M metaMe Health is the developer of Regulora®, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. in funding.
We’re excited to share that metaMe Health , a prescription digitaltherapeutics (PDT) company, today announced raising $2.2M metaMe Health is the developer of Regulora®, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. in funding.
David Horwitz, former Global Chief Medical Officer of Johnson and Johnson Diabetes Institute, will help guide strategic and development roadmap. Read more here.
Register Biofourmis , a Sigapore-founded digitaltherapeutics firm , announced that it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. Bookmark ( 0 ) Please login to bookmark Username or Email Address Password Remember Me No account yet?
a multi-billion-dollar diabetes franchise previously owned by Johnson & Johnson (JNJ) Scientific Advisory Board will help develop and execute the Company’s strategic roadmap for refining, improving and expanding its digitaltherapeutics platform. Read more here.
MedRhythms, a Portland, Maine-based digitaltherapeutics company, is building direct stimulation, prescription therapeutics that use sensors, music, and software to improve loss of mobility caused by neurologic injuries and diseases. How does MedRhythms’ technology work?
The FDA is the federal regulatory body in the United States that oversees the development of medical products (e.g. Developing and bringing a product to market will, with the exception of a limited class of products 1 , require explicit FDA marketing approval. We describe the major ones here: Therapeutic Submissions.
We organize all of the trending information in your field so you don't have to. Join 24,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content